These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25446375)

  • 1. An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.
    Ades F; Senterre C; Zardavas D; de Azambuja E; Popescu R; Parent F; Piccart M
    Eur J Cancer; 2014 Dec; 50(18):3089-97. PubMed ID: 25446375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
    Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
    Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan.
    Kondo M; Toi M
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):197-204. PubMed ID: 16445372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states.
    Ades F; Senterre C; de Azambuja E; Sullivan R; Popescu R; Parent F; Piccart M
    Ann Oncol; 2013 Nov; 24(11):2897-902. PubMed ID: 24078620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
    Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
    ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
    Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
    Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.
    Perez-Ellis C; Goncalves A; Jacquemier J; Marty M; Girre V; Roché H; Brain E; Moatti JP; Viens P; Le Corroller-Soriano AG
    Am J Clin Oncol; 2009 Oct; 32(5):492-8. PubMed ID: 19487912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of trastuzumab in metastatic breast cancer: mainly a matter of price in the EU?
    Garattini L; van de Vooren K; Curto A
    Health Policy; 2015 Feb; 119(2):212-6. PubMed ID: 25523144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden of cancer across the European Union: a population-based cost analysis.
    Luengo-Fernandez R; Leal J; Gray A; Sullivan R
    Lancet Oncol; 2013 Nov; 14(12):1165-74. PubMed ID: 24131614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
    Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
    Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S; Pilgrim H; Hind D
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?
    Rosevear M
    N Z Med J; 2006 Jun; 119(1235):U2014. PubMed ID: 16751832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
    Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
    Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab in breast cancer.
    Mastrianni DM
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470953
    [No Abstract]   [Full Text] [Related]  

  • 17. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
    Hillner BE; Smith TJ
    J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
    [No Abstract]   [Full Text] [Related]  

  • 18. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
    J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant trastuzumab for breast cancer: an increasingly common ethical and economic conundrum.
    Grove ML
    BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293847
    [No Abstract]   [Full Text] [Related]  

  • 20. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.